LivaNova PLC (NASDAQ:LIVN) Given Consensus Recommendation of “Moderate Buy” by Brokerages

LivaNova PLC (NASDAQ:LIVN) has been given an average recommendation of “Moderate Buy” by the eleven analysts that are presently covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $84.1250.

A number of research analysts have issued reports on LIVN shares. Freedom Capital raised shares of LivaNova to a “hold” rating in a report on Tuesday, June 30th. Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a report on Wednesday, August 5th. Needham & Company LLC upped their target price on LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. KeyCorp raised their target price on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Monday, June 22nd. Finally, Zacks Research cut LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th.

LivaNova Price Performance

Shares of LIVN stock opened at $78.01 on Monday. LivaNova has a fifty-two week low of $48.82 and a fifty-two week high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45. The firm has a market capitalization of $4.30 billion, a price-to-earnings ratio of 23.08 and a beta of 0.87. The stock’s 50-day simple moving average is $79.93 and its 200-day simple moving average is $73.66.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.26 EPS for the quarter, beating the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. LivaNova’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the firm posted $1.05 EPS. As a group, equities analysts forecast that LivaNova will post 3.78 earnings per share for the current fiscal year.

Insider Transactions at LivaNova

In other news, Director Brooke Story sold 2,300 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the transaction, the director directly owned 7,488 shares in the company, valued at $609,672.96. This trade represents a 23.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the sale, the director directly owned 4,434 shares of the company’s stock, valued at $345,896.34. This trade represents a 44.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 7,450 shares of company stock worth $591,839 over the last three months. Corporate insiders own 0.35% of the company’s stock.

Institutional Trading of LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of the business. Allworth Financial LP increased its stake in shares of LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after acquiring an additional 144 shares during the period. Hantz Financial Services Inc. lifted its position in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock valued at $27,000 after purchasing an additional 267 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in LivaNova in the second quarter valued at $37,000. Covestor Ltd boosted its holdings in LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock valued at $46,000 after purchasing an additional 392 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in LivaNova by 63.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 797 shares of the company’s stock worth $49,000 after purchasing an additional 308 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.